Navigation Links
Anti-Fibrotic Data from Amira Pharmaceuticals' LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
Date:5/6/2010

SAN DIEGO, May 6 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.  

The LPA1 receptor is part of the Phosphatidic Acid/ Lysophosphatidylcholine pathway and has recently been implicated for having a role in lung, kidney and skin fibrosis.  In particular, activation of the LPA1 receptor may promote fibrosis in Idiopathic Pulmonary Fibrosis (IPF), a lung disease for which there are currently no effective treatments available.

"The data in this publication demonstrate the potential of a high affinity, oral antagonist of the LPA1 receptor in diseases associated with fibrosis, edema and inflammation," said James Swaney, Ph.D., Senior Scientist at Amira and the senior author of the paper.   "Importantly, our proof of concept compound, AM966, demonstrates superior efficacy in a preclinical model when compared to other anti-inflammatory and/or anti-fibrotic agents including dexamethasone and pirfenidone.  We feel that these data pave the way for novel, 'first in class' molecules to target IPF and other fibrotic diseases via blockade of the LPA1 receptor."

Bob Baltera, Chief Executive Officer of Amira, added, "We are focused on developing LPA1 antagonists in fibrotic diseases.  Many of the potential indications address specialty care markets and give Amira the opportunity to bring a therapeutic product through to commercialization.  Grievous diseases such as IPF desperately need new therapies and the team at Amira is working hard to see these opportunities into the clinic as soon as possible."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease.  Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
2. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
3. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
4. ADVENTRX Pharmaceuticals Announces Closing of Financing
5. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
6. Trading Halted Today in Questcor Pharmaceuticals Common Stock
7. HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals
8. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
9. Alexza Pharmaceuticals Files Shelf Registration Statement
10. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
11. Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Clarifying Vision - Prospects and Developments ... Care What can be expected from the ... at the fastest rates? This visiongain report ... opportunities and prospects. ,Our 190-page report ... lucrative areas in the industry and the future market ...
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... , May 23, 2016   Purdue Pharma ... into an agreement with Egalet Corporation and Acura ... As part of the agreement the companies will ... enable all three companies to develop and sell ... "This agreement reflects the commitment of Purdue ...
Breaking Medicine Technology:
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... ... for the Surgery Center at Sentara Northern Virginia Medical Center located in Woodbridge, ... of the hospital’s surgical services into a single site. , The new 2 ...
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog Citizens Commission ... Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its protest against the ... of Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows CCHR’s recent ...
(Date:5/24/2016)... Linda, CA (PRWEB) , ... May 24, 2016 , ... ... will house the new adult hospital and expanded Children’s Hospital. Over 3,000 people looked ... 22. , Check out the event photo slidehsow. , During the program, ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... perfect data logger for each job, ensuring the best suited solution to meet ... MadgeTech data loggers at their lab in Istanbul. , Metroloji Okulu specializes in ...
(Date:5/24/2016)... ... 2016 , ... Growing in popularity, more and more people continue to live ... easily accessible. Whether someone chooses to cut gluten out of their life for personal ... Grocery stocks their shelves with many different gluten-free products all year round. And they ...
Breaking Medicine News(10 mins):